Target the Gene
Silence the Disease

Pipeline

Drug(Disease)
Disease
Phase 1
Phase 2
Phase 3
  • Fazirsiran (Alpha-1 Liver Disease)
    Alpha-1 Liver Disease
    Partnered with Takeda
  • Plozasiran
    (ARO-APOC3)     (Hypertriglyceridemia)
    Hypertriglyceridemia
  • ARO-ANG3 (Dyslipidemia)
    Dyslipidemia
  • ARO-PNPLA3 (NASH)
    NASH
  • GSK4532990 (NASH)
    NASH
    Licensed to GlaxoSmithKline
  • ARO-C3 (Complement Mediated Disease)
    Complement Mediated Disease
  • ARO-MUC5AC (Muco-obstructive)
    Muco-obstructive
  • ARO-RAGE (Inflammatory)
    Inflammatory
  • ARO-MMP7 (Idiopathic Pulmonary Fibrosis)
    Idiopathic Pulmonary Fibrosis
  • ARO-DUX4 (FSHD)
    FSHD
  • ARO-SOD1 (ALS)
    ALS
  • HZN-457 (Gout)
    Gout
    Partnered with Horizon
  • JNJ-3989 (Hepatitis B)
    Hepatitis B
    Licensed to Janssen
  • Olpasiran (Cardiovascular Disease)
    Cardiovascular Disease
    Licensed to Amgen
  • Liver
  • Lung
  • Muscle
  • CNS
Learn More

Science

Arrowhead has established a robust and versatile drug discovery and development platform based on proprietary technologies, broad licenses to fundamental intellectual property and extensive scientific expertise after more than a decade working on RNAi-based therapies.

Learn More

About Arrowhead

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes.

 

 

Learn More